Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $4.1250.

Several research firms recently commented on LUCD. BTIG Research reissued a “buy” rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a research note on Friday, May 15th. Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Wednesday, May 6th. Finally, Maxim Group cut their target price on Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, May 15th.

Insider Activity

In related news, Director Dennis Matheis bought 245,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $1.00 per share, with a total value of $245,000.00. Following the purchase, the director directly owned 1,033,443 shares of the company’s stock, valued at $1,033,443. The trade was a 31.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.80% of the stock is owned by company insiders.

Institutional Trading of Lucid Diagnostics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sprott Inc. acquired a new stake in shares of Lucid Diagnostics in the 3rd quarter worth $25,000. Centiva Capital LP acquired a new stake in shares of Lucid Diagnostics in the 3rd quarter worth $25,000. Abel Hall LLC acquired a new stake in shares of Lucid Diagnostics in the 4th quarter worth $33,000. JPMorgan Chase & Co. increased its stake in shares of Lucid Diagnostics by 71,026.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after acquiring an additional 32,672 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics in the 1st quarter worth $39,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Price Performance

Shares of LUCD stock opened at $0.97 on Friday. The company has a market cap of $196.41 million, a price-to-earnings ratio of -2.06 and a beta of 1.08. The stock has a 50 day simple moving average of $1.10 and a 200-day simple moving average of $1.17. Lucid Diagnostics has a 1-year low of $0.90 and a 1-year high of $1.63.

Lucid Diagnostics (NASDAQ:LUCD) last announced its earnings results on Thursday, May 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.38 million. Analysts anticipate that Lucid Diagnostics will post -0.22 earnings per share for the current fiscal year.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.